Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Codiak BioSciences, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Mar 2023, 17:12.
Douglas E. Williams - 28 Mar 2023 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 28 Mar 2023
- Net transaction value
- -$7,500
- SEC form
- 4
- Accepted by SEC
- 30 Mar 2023, 17:12:12 UTC
- Prior SEC filing
- 26 Jan 2023
- Next SEC filing
- 11 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Codiak BioSciences, Inc. on 30 Mar 2023.
Change
- Previous filing in this sequence was filed on 26 Jan 2023.
- Current net transaction value: -$7,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDAKQ
transaction
Common Stock
Sale
- Transaction value
- $7,500
- Shares
- -41,667
- Change %
- -84%
- Price
- $0.1800*
- Shares after
- 7,655
- Date
- 28 Mar 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.